SÜSS MicroTec AG: Cooperation of SUSS MicroTec and Swansea University's Centre for NanoHealth

SÜSS MicroTec AG: Cooperation of SUSS MicroTec and Swansea University's Centre for NanoHealth


SÜSS MicroTec AG / Key word(s): Research/Technology/

24.11.2011 / 14:19


PRESS RELEASE

Cooperation of SUSS MicroTec and Swansea University's Centre for NanoHealth

Garching (Germany) and Swansea (Great Britain), November 24, 2011 - SUSS MicroTec, a global supplier of equipment and process solutions for the semiconductor industry and related markets, announces the cooperation with Swansea University's Centre for NanoHealth (CNH). This cooperation is linked to CNH's recent purchase of a SUSS Mask Aligner, MA/BA8 Gen3 with SCIL option. SCIL (Substrate Conformal Imprint Lithography) is a technology for large area imprint that enables patterning at nano scale, whilst maintaining consistent uniformity over entire wafer areas.

The research of CNH is addressing challenges in healthcare such as developing next generation solutions to enable early intervention and detection of diseases followed by immediate identification of appropriate treatments. The Centre is backed by the European Regional Development Fund through the Welsh Government to address some of the biggest challenges facing the future of healthcare such as enhancing early intervention in diagnosing and treating diseases in non-hospial environments; in the home, community clinic or local doctors' surgery. This can be achieved through the use of devices such as biosensors to detect disease-relevant biomarker for heart disease, cancer, diabetes or other chronic conditions.

The SUSS Mask Aligner will facilitate the processing of such novel technologies by applying micro/nano fabrication methods to produce biosensors, bioMEMS devices, microfluidics and photonics.

'There are enormous opportunities in the biomedical industry. BioMEMS devices are the platform through which the nanomedicine applies.' states Frank P. Averdung, President and CEO of SÜSS MicroTec AG. 'We believe that with the establishment of economical production processes the emerging bioMEMS segment is about to exceed the threshold to become a fast growing market. Our innovative nano imprint solution will enable CNH to develop production processes on large area wafers which is the key to rapid transfer of prototype technologies to cost effective volume production and commercialisation.'

Dr. Matt Elwin, Centre Manager for the Centre for NanoHealth said, 'The SUSS MicroTec Aligner will be an essential tool for the development of sensors and devices within the CNH, and there are already numerous projects vying for equipment time. The additional capabilities of SCIL will also open up new possibilities and we are excited about the potential of this new technique. SUSS MicroTec has made a significant contribution to the CNH project, and we are looking forward to developing its applications in the fabrication of new biosensors and medical devices.'

About SUSS MicroTec
SÜSS MicroTec AG, listed in the German technology index TecDAX, is a leading supplier of equipment and process solutions for microstructuring in the semiconductor industry and related markets. In close cooperation with research institutes and industry partners SUSS MicroTec contributes to the advancement of next-generation technologies such as 3D Integration and nanoimprint lithography as well as key processes for MEMS and LED manufacturing. With a global infrastructure for applications and service SUSS MicroTec supports more than 8,000 installed systems worldwide. SUSS MicroTec is headquartered in Garching near Munich, Germany. For more information, please visit http://www.suss.com.

About Swansea University's Centre for NanoHealth
The Centre for NanoHealth (CNH) is a unique open access interdisciplinary research centre based on the application of Nanotechnology leading innovations in Healthcare. This joint initiative between the Colleges of Medicine, Engineering & Science at Swansea University, and the Abertawe Bro Morgannwg University NHS Health Board offers exciting opportunities to work at the interface between Engineering Biomedical Science and clinical delivery, through access to a wide range of academic and clinical expertise and partnerships, as well as state of the art nanotechnology and biomedical R&D facilities. For further information, please visit http://www.nanohealth.swansea.ac.uk.




Contact:
SUSS MicroTec AG
Franka Schielke
Schleissheimer Strasse 90
85748 Garching, Deutschland
Tel.: +49 (0)89 32007-161
Fax: +49 (0)89 32007-451
Email: franka.schielke@suss.com



End of Media Release


24.11.2011 Dissemination of a Press Release, transmitted by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de



147589  24.11.2011